DAVENPORT & Co LLC Increases Stake in The Cooper Companies, Inc. $COO

DAVENPORT & Co LLC increased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 770.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 38,857 shares of the medical device company’s stock after purchasing an additional 34,391 shares during the period. DAVENPORT & Co LLC’s holdings in Cooper Companies were worth $2,664,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Cooper Companies by 1.8% in the second quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock worth $1,725,963,000 after purchasing an additional 421,423 shares during the last quarter. State Street Corp raised its holdings in shares of Cooper Companies by 1.2% in the second quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock worth $616,227,000 after buying an additional 104,910 shares during the period. Geode Capital Management LLC lifted its stake in shares of Cooper Companies by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock worth $368,893,000 after acquiring an additional 127,907 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Cooper Companies by 17.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock valued at $399,340,000 after acquiring an additional 686,751 shares during the period. Finally, Ameriprise Financial Inc. grew its position in Cooper Companies by 98.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after acquiring an additional 1,683,561 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Zacks Research raised multiple near‑ and medium‑term EPS forecasts (including FY2026 to $4.45, FY2027 to $4.84 and FY2028 to $5.33) and lifted several quarterly estimates — this improves the earnings trajectory and supports valuation multiple expansion.
• Positive Sentiment: Zacks specifically increased Q1 2026 to $1.02, Q2 2026 to $1.07, Q3 2026 to $1.16 and Q4 2026 to $1.20 (and raised several 2027 quarter estimates), signaling confidence in near‑term revenue/margin trends.
• Positive Sentiment: Brokerage consensus flagged a “Moderate Buy” for COO, which can attract incremental demand from models and investors that follow analyst ratings. Article Title
• Neutral Sentiment: A Zacks comparison piece examines COO vs. Merit Medical (MMSI) for value investors — useful for relative‑value decisions but not a direct catalyst. Article Title
• Neutral Sentiment: December short‑interest data in the report is effectively zero/NaN and appears unreliable; it provides no actionable signal on short pressure or squeeze risk at present.
• Negative Sentiment: One small downward tweak: Zacks trimmed Q3 2027 EPS from $1.25 to $1.24 — a minor cut that slightly offsets some upgrades but is not material to the overall upward revisions.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on COO shares. Barclays reiterated an “overweight” rating and set a $91.00 target price on shares of Cooper Companies in a research report on Monday, December 8th. Wells Fargo & Company upped their target price on shares of Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, December 5th. Citigroup reaffirmed a “neutral” rating and set a $88.00 target price (up from $72.00) on shares of Cooper Companies in a research report on Monday, December 8th. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research note on Friday, December 5th. Finally, Stifel Nicolaus set a $95.00 price objective on Cooper Companies and gave the stock a “buy” rating in a research note on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $90.15.

Cooper Companies Price Performance

Shares of COO opened at $82.62 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. The company has a 50 day moving average price of $75.92 and a 200-day moving average price of $72.44. The Cooper Companies, Inc. has a fifty-two week low of $61.78 and a fifty-two week high of $100.24. The stock has a market capitalization of $16.19 billion, a PE ratio of 43.95, a PEG ratio of 2.36 and a beta of 1.05.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. Cooper Companies’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies declared that its board has initiated a stock buyback program on Wednesday, September 17th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Insider Activity

In other news, Director Maria Rivas bought 1,000 shares of Cooper Companies stock in a transaction on Thursday, December 18th. The stock was acquired at an average cost of $82.13 per share, for a total transaction of $82,130.00. Following the completion of the acquisition, the director owned 11,141 shares of the company’s stock, valued at $915,010.33. This trade represents a 9.86% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Albert G. White III purchased 10,000 shares of the stock in a transaction dated Tuesday, December 16th. The stock was purchased at an average price of $80.80 per share, for a total transaction of $808,000.00. Following the completion of the acquisition, the chief executive officer directly owned 236,151 shares in the company, valued at approximately $19,081,000.80. This represents a 4.42% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 18,014 shares of company stock worth $1,441,196 over the last ninety days. 1.98% of the stock is currently owned by corporate insiders.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.